Plato Investment Management Ltd Sells 17,273 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Plato Investment Management Ltd lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 27.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,257 shares of the company’s stock after selling 17,273 shares during the period. Plato Investment Management Ltd’s holdings in Teva Pharmaceutical Industries were worth $1,023,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of TEVA. Smithfield Trust Co lifted its holdings in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $50,000. Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. Ameliora Wealth Management Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $66,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 273.5% during the third quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock worth $82,000 after purchasing an additional 3,323 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $16.01 on Tuesday. The firm’s 50-day moving average price is $19.41 and its 200-day moving average price is $18.46. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The firm has a market capitalization of $18.15 billion, a P/E ratio of -11.04, a P/E/G ratio of 1.44 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on TEVA shares. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.